Eurifel RCP FeLV

Withdrawn

This medicine's authorisation has been withdrawn

vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats

Overview

The marketing authorisation for Eurifel RCP FeLV has not been renewed by the marketing authorisation holder and is now withdrawn.

Product information

Product details

• Name of medicine:
  Eurifel RCP FeLV
• Active substance:
  • canarypox virus expressing feline leukemia virus, live
  • feline calicivirus, strain 255, inactivated
  • feline panleucopenia virus, strain PLI IV, live
  • feline rhinotracheitis virus, strain C27, antigen
• International non-proprietary name (INN) or common name:
  vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats
• Species:
  Cats
• Anatomical therapeutic chemical veterinary (ATCvet) code:
  QI06AH

Pharmacotherapeutic group

Immunologicals for felidae

Therapeutic indication

Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia.

Stimulates active immunity against feline rhinotracheitis virus, feline calicivirus, feline panleucopenia virus and feline leukaemia virus.

The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A. Under field conditions, only sub-group A is infective and immunisation against subgroup A provides full protection against A, B and C. After inoculation, the virus expresses the protective proteins, but does not replicate in the cat. As a consequence, the vaccine induces an immune status against feline leukaemia virus.

Authorisation details

• EMA product number:
  EMEA/V/C/000067
• Marketing authorisation holder:
  Merial

  29, avenue Tony Garnier; 69007 Lyon; FRANCE

• Marketing authorisation issued:
  08/03/2002
• Revision:
  8